Decoy Therapeutics D-MAV candidate shows in vitro activity against Ebola Zaire virus

PUBT · 2d ago
Decoy Therapeutics D-MAV candidate shows in vitro activity against Ebola Zaire virus
  • Decoy Therapeutics reported a D-MAV candidate showed in vitro activity against wild-type Ebola Zaire in tests at Texas Biomedical Research Institute.
  • Result broadened the platform beyond coronaviruses, where the same candidate has shown nanomolar to picomolar activity across known strains.
  • Company opened an exploratory filovirus program to design D-MAVs targeting Ebola and Marburg, positioning the platform for pandemic preparedness.
  • Candidate also showed in vitro activity against Lassa fever virus, supporting a cross-viral family fusion-inhibition approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE12112) on July 27, 2026, and is solely responsible for the information contained therein.